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Summary 
BACKGROUND: Based on a reduction in morbidity and mortality, car-
diac resynchronisation therapy (CRT) has evolved as a standard ther-
apy for patients with advanced heart failure. 
OBJECTIVE: To provide insight into patient demographics, safety, echo-
cardiographic remodelling and long-term follow-up of patients treated 
with CRT in a “real-world” setting at a Swiss tertiary care centre. 
METHODS: Patients implanted with a CRT device at the University 
Heart Centre Zurich between 2000 and 2015 were consecutively en-
rolled. Initial clinical and echocardiographic therapy response as well 
as long-term follow-up for mortality (defined as all-cause death, heart 
transplantation or ventricular assist device implantation) and hospital-
isation for heart failure were assessed. 
RESULTS: A total of 418 patients with a median age of 66 years at the 
time of CRT implantation (78% male) were enrolled. Serious peri-inter-
ventional complications (from the time of implantation up to 14 days 
thereafter) were rare and included systemic infections in 2.4%, pneu-
mothorax in 3.3% and haematoma requiring revision in 2.2% of cases. 
Overall, the Kaplan-Meier estimate for 5-year freedom from the com-
posite endpoint (hospitalisation for heart failure or mortality) was 
55.8%; the Kaplan-Meier estimate for 5-year freedom from mortality 
was 64.1%. CRT was associated with a significant symptomatic im-
provement and left ventricular reverse remodelling. 
Overall, 3.9% of patients did not respond to cardiac resynchronisation 
therapy (decline in left ventricular ejection fraction [LVEF] >5%), 
whereas 35.1% experienced neither a continued decline nor a relevant 
improvement of LVEF (±5%). In the remaining 61% of patients we ob-
served an improvement in LVEF of more than 5%. Forty percent and 
31% of patients were super responders, defined as an absolute LVEF 
improvement of 10% and by a relative reduction of left ventricular 
end-diastolic volume index by 20% or more. Super-response to CRT 
was associated with a significant benefit in terms of survival and re-
hospitalisation rates. 
CONCLUSION: Our data are consistent with large multicentre trials and 
indicate that CRT is similarly effective in a real-world setting in Swit-
zerland. 
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Introduction 
On the basis of accumulating evidence demonstrating its safety and ef-
fectiveness, cardiac resynchronisation therapy (CRT) has emerged as a 
standard of care in patients with heart failure and severely reduced left 
ventricular ejection fraction (HFrEF) [1–5]. During recent years, how-
ever, selection criteria for CRT have changed substantially. Initially, 
the benefit of CRT was demonstrated for highly symptomatic patients 
(New York Heart Association [NYHA] class III and ambulatory IV) 
with a left ventricular ejection fraction (LVEF) 35% [1–3]; growing 
evidence has since shown a reduction in morbidity and mortality also 
in oligosymptomatic patients (NYHA II) [4, 5]. Hence, current guide-
lines for the diagnosis and treatment of acute and chronic heart failure 
recommend CRT as standard therapy in symptomatic patients with an 
LVEF ≤35% despite optimal medical therapy and a QRS complex ≥130 
ms [6]. In contrast, patients with a narrow QRS complex (<120 ms and 
<130 ms) do not seem to benefit from CRT and may, in some cases, 
even derive harm [7, 8]. 
Whether the positive results observed in the above-mentioned large, 
randomised, controlled trials also translate to patients selected in daily 
clinical practice in Switzerland is less clear [9]. Indeed, a considerable 
number of patients do not respond to CRT [9, 10]. Therefore, observa-
tional research in a “real-world” setting, i.e. registries and surveys, is 
important to assess the safety and efficacy of evolving therapies in daily 
clinical practice [9, 11, 12]. Consecutive enrolment into such registries 
largely avoids the often criticised selection bias of interventional trials. 
In the current study we aimed to provide an update to our previously 
published results [9, 13], not only with respect to patient demographics, 
but also regarding periprocedural safety, echocardiographic response 
and long-term outcome. 
Methods 
Study population and follow-up 
From November 2000 to July 2015 all patients implanted with a CRT 
device at the University Heart Centre Zurich and who provided in-
formed consent were consecutively enrolled. Patients were followed up 
for clinical and echocardiographic improvement (left ventricular re-
modelling), as well as for hospitalisation for heart failure and mortality 
 (defined as death from any cause, heart transplantation or ventricular 
assist device [VAD] implantation). Clinical and echocardiographic fol-
low-up was performed in-house or by the patients’ private cardiologist. 
Long-term follow-up involved a telephone interview and/or chart re-
view, either in-house or in cooperation with the family physician. Def-
inition of clinical and echocardiographic therapy response as well as 
definition of outcomes (all-cause death, heart transplantation or ventric-
ular assist device implantation and hospitalisation for heart failure) was 
defined post hoc. The study was approved by the local ethics committee 
(KEK-ZH-NR: 2011-0304). All enrolled patients provided informed 
consent. 
CRT implantation 
The vast majority of transvenous leads were implanted under local an-
aesthesia with mild conscious sedation. Devices and leads of the ven-
dors Biotronik, Guidant / Boston Scientific, Medtronic, St. Jude Medi-
cal, and Sorin / LivaNova were implanted. After intubation of the cor-
onary sinus, a coronary sinus venogram was obtained during transient 
balloon occlusion of the coronary sinus in order to visualise vessel anat-
omy. Target veins were either lateral or posterolateral coronary veins, 
to achieve optimal separation of right and left ventricular pacing. Left 
ventricular leads were advanced into the target vein in an over-the-wire 
technique. When transvenous coronary sinus lead placement was not 
possible because of either anatomical or technical obstacles, an epicar-
dial lead was placed via a separate approach. Documented peri-inter-
ventional complications included any complication between the time of 
device implantation and 14 days thereafter. Decision to implant a CRT-
pacemaker (CRT-P) or CRT-defibrillator (CRT-D) was left to the clin-
ical judgment of the treating physician, based on a patient-centred ap-
proach taking into account individual risk stratification, physician ex-
perience, cost-effectiveness and patient expectations. 
Echocardiographic super-response was defined post-hoc as either an 
absolute improvement of LVEF by ≥10% or a relative reduction of the 
left ventricular end-diastolic volume index (LVEDVI) by 20% or more. 
Statistical analysis 
Continuous variables are presented as medians and interquartile ranges 
(IQRs), if not indicated otherwise. Categorical and ordinal variables are 
presented as patient number per total number and percentage. Pre- and 
postoperative values of continuous and ordinal variables were com-
pared using Wilcoxon signed rank tests. All p-values are two-sided. 
Survival curves for time-to-event variables were constructed using 
Kaplan-Meier estimates based on all available data. Survival curves of 
different patient groups were compared using log-rank tests. Signifi-
cance was accepted for p <0.05. All statistical analyses were performed 
in IBM SPSS Statistics, version 22. 
Results 
Baseline characteristics 
Between November 2000 and July 2015, 418 patients were implanted 
with a CRT device. Median age at the time of implantation was 66 
years. The leading cause of cardiomyopathy was ischaemic (n = 175, 
41.9%), followed by dilative cardiomyopathy (n = 157, 37.6%). Median 
time from diagnosis of heart failure (HF) to CRT implantation was 14 
months. Baseline characteristics were rather constant across the differ-
ent time periods of device implantation (table 1 and supplementary ta-
ble S1 in appendix). 
At the time of CRT implantation, the majority of patients were on state-
of-the-art medical heart failure therapy with angiotensin converting-en-
zyme (ACE) inhibitors or angiotensin receptor blockers (90.7%), beta 
blockers (80.1%), loop diuretics (74.6%), and aldosterone antagonists 
(51.7%) (table S2). Most patients were symptomatic, with dyspnoea 
NYHA class II (n = 108, 26.1%) or class III (n = 250, 60.4%) (table 1). 
Median LVEF was 26% (table 1, table S3). A baseline electrocardio-
gram revealed sinus rhythm in 70.4% of patients (n = 293), atrial fibril-
lation in 11% (n = 46), and a paced rhythm in 18.7% (n = 78). Exclud-
ing paced patients, 16.7% (n = 57) had a QRS width <120 ms. The ma-
jority of patients (71.8%, n = 247) had left bundle-branch block; only a 
minority of 5.5% (n = 19) presented with a right bundle-branch block 
(table 1, table S4). 
 
Table 1: Patient characteristics at baseline (the time of cardiac resynchronisation 
therapy implantation). 
Age at implantation – years 66 (58–73) 
Male sex – no. / total no. (%) 325/418 (77.8) 
Height – m 1.72 (1.65–1.77) 
Weight – kg 78 (68–88) 
BMI – kg/m2 26.6 (23.6–30.3) 
Body surface area – m2 1.93 (1.79–2.07) 
Ischaemic cardiomyopathy – no. / total no. (%) 175/418 (41.9) 
Blood pressure while sitting – mm Hg  
Systolic 114 (102–128) 
Diastolic 70 (60–77) 
Heart rate – min-1 72 (63–81) 
Creatinine – mol/l 106 (88–140) 
proBNP – ng/ml 2138 (981–4581) 
Na+ – mmol/l 139 (137–141) 
K+ – mmol/l 4.2 (3.9–4.6) 
NYHA class – no. / total no. (%)  
I 24/414 (5.8) 
II 108/414 (26.1) 
III 250/414 (60.4) 
ambulatory IV 27/414 (6.5) 
Systemic arterial hypertension – no. / total no. (%) 222/418 (53.1) 
Prior stroke – no. / total no. (%) 35/417 (8.4) 
Diabetes – no. / total no. (%) 105/418 (25.1) 
Coronary artery disease – no. / total no. (%) 209/417 (50.0) 
Chronic obstructive lung disease – no. / total no. (%) 37/418 (8.9) 
Time of diagnosis to CRT implantation – months 14.1 (2.1–73.1) 
Left ventricular ejection fraction – %, n = 412 26 (20–32) 
Sinus rhythm – no. / total no. (%) 293/417 (70.3) 
QRS duration – ms 151 (130–170) 
QRS 120 ms – no. / total no. (%) 57/342 (16.7) 
QRS >120 ms to 150 ms – no. / total no. (%) 111/342 (32.5) 
QRS >150 ms – no. / total no. (%) 174/342 (50.9) 
Left bundle-branch block – no. / total no. (%) 247/344 (71.8) 
BMI = body mass index; CRT = cardiac resynchronisation therapy; NYHA = New 
York Heart Association; proBNP = pro-B-type natriuretic peptide 
Categorical variables are presented as patient number per total number and per-
cent total; continuous variables are presented as median and interquartile ranges, 
if not indicated otherwise. 
 
Implantation procedure 
Initial left ventricular lead placement was successful in 88% of patients 
(n = 366). In the remaining 52 patients (12.4%), left ventricular lead 
placement was successful during a second attempt. Overall, 11.5% 
(n = 48) received an epicardial left ventricular lead via a surgical ap-
proach. Of these 48 surgical left ventricular lead placements, 16 were 
primary surgical approaches, whereas 32 were performed after an ini-
tial, unsuccessful transvenous attempt (table S5A). The median dura-
tion of the associated hospital stay was 2 days (table S5A). Complica-
tions, which were documented from the time of device implantation un-
til 14 days thereafter, occurred in a limited number of cases (table S5B). 
The most common complications were left ventricular lead dislocation 
(5.5%, n = 23), infection (local 2.2%, n = 9; systemic, necessitating de-
vice extraction 2.4%, n = 10), pneumothorax (3.3%, n = 14), and hae-
matoma necessitating revision (2.2%, n = 9). There were no peri-inter-
ventional deaths. In 10.6% of cases (n = 44) post-interventional dia-
phragmatic capture occurred. Reprogramming was sufficient to abolish 
diaphragmatic capture in the majority of cases (6.2%, n = 26); left ven-
tricular lead repositioning was successfully performed in 5 patients 
 (1.2%). In 11 patients (2.6%) with only intermittent diaphragmatic cap-
ture, no intervention was necessary, and in the remaining 2 patients 
(0.5%) left ventricular pacing had to be discontinued (table S5B). 
Postoperative course and echocardiographic follow-up 
At clinical follow-up after a median time of 5.9 months from CRT im-
plantation, which was available for 305 patients (73%), 63.5% of pa-
tients reported symptomatic improvement of at least one point on the 
NYHA scale. Overall, the proportion of patients in lower NYHA cate-
gories increased significantly compared with the NYHA distribution 
before CRT implantation (fig. 1). 
 
 
 
 
Figure 1: Clinical effects of cardiac resynchronisation therapy (CRT). Distribution of 
New York Heart Association (NYHA) class before and after CRT implantation (data 
available in 305 patients, 73%). Median follow-up time of 6 months. Wilcoxon signed 
rank test. 
 
 
Echocardiographic follow-up was available for 369 patients (88.3%). A 
median absolute increase in LVEF of 7% from 26% to 33% (fig. 2A) 
was observed across the entire study group. Only 3.9% of patients ex-
perienced a continued decline in LVEF (>5%) and, thus, did not re-
spond to CRT. In 35.1% of patients we observed neither a continued 
decline nor a relevant improvement of LVEF (±5%). In the remaining 
61% of patients we observed an improvement of the LVEF of more than 
5%. Based on an absolute improvement of LVEF of 10%, 40% of pa-
tients (n = 146/365) were considered super-responders. Based on a rel-
ative reduction of the LVEDVI by 20% or more, 31% of patients 
(n = 50/288) were super-responders. Fifty-one percent of patients 
demonstrated a relevant decline (reduction of >10%), whereas 38% had 
no relevant change in LVEDVI (±10%) and 11% experienced an in-
crease in LVEDVI by 10% or more. Over the entire population median 
LVEDVI, left ventricular endsystolic volume index (LVESVI), and left 
atrial endsystolic diameter (LAESD) were significantly reduced (fig. 
2A). Mitral regurgitation also improved following CRT implantation 
(fig. 2B). Interestingly, we observed a reduction of the systolic right 
ventricular over right atrial pressure from a median of 30 mm Hg to a 
median pressure of 26 mm Hg (fig. 2A). No difference was found in 
right ventricular fractional area change and tricuspid annular movement 
(fig. 2A). 
Excluding patients with right ventricular pacing at baseline, we ob-
served consistently higher proportions of positive echocardiographic 
response in those patients with a left bundle-branch block morphology 
compared with those without (table S6). 
Long-term clinical follow-up 
Patients were followed-up for rehospitalisation for heart failure, heart 
transplantation, implantation of a left ventricular assist device (LVAD) 
and death for a median time of 3.6 years (IQR 1.9–5.7 years) after CRT 
implantation. The Kaplan-Meier estimate for freedom from the compo-
site endpoint of hospitalisation for heart failure and mortality (all-cause 
death, heart transplantation or ventricular assist device [VAD] implan-
tation) at 5 years after CRT implantation was 55.8%. The Kaplan-Meier 
estimate for freedom from mortality (all-cause death, heart transplanta-
tion or VAD implantation) at 5 years after CRT implantation was 64.1% 
(fig. 3, table 2). 
Both groups of super responders – patients with an absolute LVEF im-
provement of 10%, and patients with a relative LVEDVI reduction of 
20% – had a significantly improved survival and freedom from hospi-
talisation for heart failure compared with the corresponding control 
groups (fig. 4, table 2). Accordingly, 5-year estimates both for freedom 
from the composite endpoint of mortality or hospitalization for heart 
failure, as well as for mortality alone were higher in either super-re-
sponder group compared to the respective remaining patient population 
(fig. 4, table 2). 
 
 
Table 2: Endpoints during long-term follow-up. 
Death – no. / total no. (%) 140/418 (33.5) 
Heart transplantation – no. / total no. (%) 16/418 (3.8) 
VAD implantation – no. / total no. (%) 14/418 (3.3) 
First hospitalisation for heart failure – no. / total no. 
(%) 
101/399 (25.3) 
VAD = ventricular assist device 
 
 
  
Figure 2: Effects of cardiac resynchronisa-
tion therapy (CRT) on echocardiographic re-
verse remodelling. Comparisons pre- vs 
post-CRT implantation of echocardio-
graphic parameters of cardiac remodelling. 
(A) Comparisons of LVEF (left ventricular 
ejection fraction), LVEDVI (left ventricular 
end-diastolic volume index), LVESVI (left 
ventricular endsystolic volume index), 
LAESD (left atrial endsystolic diameter), 
RV/RA (systolic right ventricular over right 
atrial pressure), RV RAC (right ventricular 
fractional area change), TAM (tricuspid an-
nular movement). (B) Comparison of mitral 
regurgitation. Wilcoxon singed rank tests. 
Box plots show interquartile ranges, whisk-
ers indicate minimum and maximum val-
ues. Median follow-up time of 6 months. 
Follow-up echocardiographic data were 
available for 369 patients (88.3%). 
 
 
 
  
 
Figure 3: Follow-up for survival and rehospitali-
sation for congestive heart failure. Kaplan-Meier 
survival estimates for (A) the composite end-
point of hospitalisation for heart failure or all-
cause mortality (defined as death, heart trans-
plantation or ventricular assist device implanta-
tion) and (B) the endpoint of mortality alone. 
Follow-up began at the time point of cardiac re-
synchronisation therapy implantation. Median 
follow-up time was 3.6 years (interquartile range 
1.9–5.7). 
 
Figure 4: Subgroup analyses for super-respond-
ers to cardiac resynchronisation therapy (CRT). 
Kaplan-Meier survival estimates for the compo-
site endpoint of hospitalisation for heart failure 
and mortality (defined as death, heart transplan-
tation or ventricular assist device  implantation) 
as well as for mortality alone. (A, B) Comparison 
of the subgroups of super-responders by left 
ventricular ejection fraction (LVEF) (absolute 
LVEF increase of 10% or greater) with non-su-
per-responders.  (C, D) Comparison of super-re-
sponders by left ventricular end-diastolic volume 
index (LVEDVI) (reduction of 20% or greater) 
with non-super-responders. Groups were com-
pared with log rank tests. Follow-up began at 
the time point of CRT implantation. Median fol-
low-up time was 3.6 years (interquartile range 
1.9–5.7). 
 
 
 
  
 Discussion 
The present real-world experience of patients with CRT supports the 
beneficial effects of CRT observed in large randomised trials. CRT is 
associated with a marked symptomatic improvement and left ventricu-
lar reverse remodelling in patients with advanced heart failure. A sub-
stantial number of patients were super-responders, which was associ-
ated with a significant survival benefit compared with the remaining 
patient population. Only a few patients did not profit from CRT and 
experienced a continued decline in left ventricular function. 
CRT has evolved as an integral therapeutic modality for patients with 
advanced heart failure and reduced ejection fraction. However, there is 
often uncertainty as to whether patient populations from large clinical 
trials truly represent the patients encountered in daily clinical practice. 
Therefore, in order to evaluate the benefit of comparatively novel ther-
apies such as CRT, it is prudent to analyse their safety and effectiveness 
under real-world conditions. 
Constant technical advancement of the material (guiding catheters, 
leads) has made the implantation of left ventricular leads easier than in 
the early years of CRT. In our current cohort, left ventricular lead place-
ment was successful during the initial session in 87.5% of cases. Im-
portantly, transvenous left ventricular lead placement was performed 
only in presence of an appropriate target vessel (lateral or posterolateral 
vein). Pro forma implantation, such as into an anterior cardiac vein, 
which has been shown to be of little benefit in cardiac resynchronisation 
[14, 15], was avoided. In such cases an epicardial lead was surgically 
implanted via mini-thoracotomy, if surgical risk was deemed accepta-
ble. 
Independent of its beneficial effect on morbidity and mortality, CRT 
implantation is an invasive procedure and, therefore, is associated with 
a certain risk of periprocedural complications. Overall, complications 
occurred in a limited number of cases and were comparable with other 
registries, such as the European CRT Survey [12]. Of note, the Euro-
pean registry reported complications only until hospital discharge, 
whereas our registry included complications up to 14 days after CRT 
implantation. Importantly, the necessity of left ventricular lead reposi-
tioning due to phrenic nerve capture or insufficient left ventricular cap-
ture has become increasingly rare since the use of quadripolar leads be-
gan in 2011. 
The current registry included 418 CRT implantations at our centre. 
Consecutive enrolment reduced any possible bias to a minimum. The 
demographics of our cohort are very similar to those of the large clinical 
trials and also closely resemble the baseline characteristics of the pa-
tient cohort in the European CRT Survey (which included 2438 patients 
enrolled at 141 centres in 13 countries) [12]. Interestingly, patient de-
mographics remained largely unchanged compared with the beginning 
of data collection in 2010 [16], and represent a typical heart failure pop-
ulation. 
Before the EchoCRT trial, a number of small studies suggested that pa-
tients with echocardiographic dyssynchrony and a narrow QRS com-
plex (<120 ms) may profit from CRT [17–20]. However, EchoCRT 
demonstrated the opposite: CRT may even increase mortality in pa-
tients with a narrow QRS complex, irrespective of echocardiograph-
ically evident mechanical dyssynchrony [7]. The reasons for this find-
ing are the subject of current research and ongoing analyses. The sub-
stantial number of patients with a QRS >120 ms in our overall cohort 
(85%) largely reflects the practice of CRT implantation prior to 
EchoCRT. Since then, only a few patients with narrow QRS received 
CRT for specific indications, such as an expected high percentage of 
right ventricular pacing in the presence of an atrioventricular block [21] 
or upgrades from chronic right ventricular pacing [22] as these patient 
subgroups may benefit more from biventricular pacing than from right 
ventricular pacing only. 
Our data further indicate that in this real-world cohort of consecutively 
included patients, CRT results in substantial reverse left ventricular re-
modelling and marked clinical improvement. In the absence of a uni-
form definition of super-response, two frequently employed cut-offs 
were used, yielding very similar results. Up to 40% of patients turned 
out to be super-responders, who in turn displayed a survival benefit. In 
the majority of the remaining patients, further deterioration of left ven-
tricular function could be avoided, which in itself may be considered a 
form of response to CRT [23]. CRT had probably no effect on the nat-
ural course of declining left ventricular function in only a minority of 
patients (4 to 11%). Importantly, however, overall Kaplan-Meier sur-
vival estimates constitute a 5-year freedom from the composite end-
point of all-cause death, VAD implantation, heart transplantation or 
hospitalisation for heart failure of 55.8%, and a 5-year survival free of 
heart transplantation or LVAD implantation of 64.1% – both of which 
are at least as high as those in the available large clinical trials or regis-
tries [11, 12, 24, 25]. 
Limitations 
The current study has to be interpreted in the light of the following lim-
itations, most of which are inherent to any single-centre real-world ob-
servational study. All patients were recruited at a single centre, which 
may introduce a selection as well as a referral bias. Clinical and echo-
cardiographic follow-up is incomplete, which is owing to frequent pa-
tient referral from out-patient care-givers, limiting at least in part acces-
sibility to external patient data. Importantly, however, long-term fol-
low-up for hard endpoints including survival and hospitalisation for 
worsening heart failure are very complete. As a result of the consecutive 
enrolment of patients until July 2015, follow-up time ranges from <6 
months (7.7% of patients) to 13.2 years. Median follow-up time was 3.6 
years. Moreover, echocardiographic response to CRT based on LVEF 
is inherently limited by intra-observer variability, which is reported to 
range from 6 to 10%. Therefore, we defined any change in LVEF of 
±5% as “no relevant change”. Echocardiographic super-response lacks 
a universal definition. We therefore applied two different definitions of 
different sensitivity: an absolute LVEF increase of >10% and, more 
sensitive, a relative LVEDVI reduction of >20%. Importantly, both def-
initions were associated with a significantly better outcomes for sur-
vival and rehospitalisation due to worsening heart failure. 
Implications and perspectives 
CRT remains an important part of current heart failure therapy. Based 
on the results of landmark clinical trials, patient selection for CRT is 
continuously optimised, resulting in a further refinement of patients se-
lected for this therapy. Our real-world analysis from a large Swiss ter-
tiary centre confirmed the findings of pivotal clinical trials and show 
that, in a real-world setting of everyday clinical practice, CRT is safe 
and effective. In order for patients to derive the maximum benefit from 
this important therapy, implantation at centres with sufficient volume 
and experience in the implantation procedure and the dedicated follow-
up of these patients is critical [11, 26]. 
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 Appendix: Supplementary tables 
 
Table S1: Patient characteristics at baseline stratified according to the time period of cardiac resynchronisation therapy device implantation. 
 Patient group (no. / % total) 
2000–2005 
(35/8.4) 
2006-2010 
(204/48.8) 
2011-2015 
(179/42.8) 
Age at implantation – years 64 (57–72) 66 (58–72) 68 (60–74) 
Male sex – no. / total no. (%) 35/35 (n.a.) 152/204 (74.5) 138/179 (77.1) 
Height – m 1.74 (1.7–1.78) 1.72 (1.65–1.77) 1.72 (1.64–1.77) 
Weight – kg 85 (74–96) 79 (70–88) 76 (66–88) 
BMI – kg/m2 26.9 (24.2–32.3) 26.9 (24.1–30.3) 25.7 (22.7–29.4) 
Body surface area – m2 2.02 (1.88–2.16) 1.95 (1.81–2.07) 1.90 (1.75–2.04) 
Ischaemic cardiomyopathy – no. / total no. (%) 17/35 (48.6%) 94/204 (46.1) 64/179 (35.8) 
Blood pressure while sitting – mm Hg    
Systolic 111 (110–126) 111 (104–125) 118 (100–132) 
Diastolic 70 (60–75) 70 (62–78) 68 (58–76) 
Heart rate – min-1 72 (68–80) 72 (64–80) 70 (62–81) 
Creatinine – mol/l 126 (105–145) 107 (88–139) 101 (86–140) 
proBNP – ng/ml 1808 (1030–3485) 2138 (988–4704) 2308 (944–4207) 
Na+ – mmol/l 137 (136–140) 140 (138–141) 139 (137–140) 
K+ – mmol/l 4.3 (3.9–4.7) 4.2 (3.8–4.5) 4.2 (3.9–4.7) 
NYHA classification – no. / total no. (%)    
I 1/35 (2.9) 11/202 (5.5) 17/177 (9.6) 
II 11/35 (31.4) 36/202 (17.8) 61/177 (34.5) 
III 22/35 (62.9) 140/202 (69.3) 88/177 (49.7) 
ambulatory IV 1/35 (2.8) 15/202 (7.4) 11/177 (6.2) 
Systemic arterial hypertension – no. / total no. (%) 19/35 (54.3) 97/204 (47.6) 109/179 (60.9) 
Prior stroke – no. / total no. (%) 1/35 (2.9) 18/203 (8.9) 16/179 (8.9) 
Diabetes – no. / total no. (%) 9/35 (25.7) 51/204 (25.0) 45/179 (25.1) 
Coronary artery disease – no. / total no. (%) 17/35 (48.6) 96/203 (47.3) 96/179 (53.6) 
Chronic obstructive lung disease – no. / total no. (%) 3/35 (8.6%) 19/204 (9.3) 15/179 (8.4) 
Time of diagnosis to CRT implantation – months 8.9 (0.7–50.8) 6.5 (1.7–46.3) 30.6 (4.7–108.7) 
Left ventricular ejection fraction – %, total n = 412 20 (17–28) 17 (20–31) 28 (21–33) 
Sinus rhythm – no. / total no. (%) 15/34 (44.1) 145/204 (71.1) 133/179 (74.3) 
QRS duration – ms 170 (137–193) 155 (130–180) 157 (134–176) 
Left bundle-branch block – no. / total no. (%) 17/35 (48.6%) 121/204 (59.3) 117/179 (65.4) 
BMI = body mass index; CRT = cardiac resynchronisation therapy; NYHA = New York Heart Association; proBNP = pro-B-type natriuretic peptide 
Categorical variables are presented as patient number per total number and percent total; continuous variables are presented as median and interquartile range, if not indi-
cated otherwise. 
 
Table S2: Cardiac medication at the time of cardiac resynchronisation therapy device implanta-
tion. 
 No. / total no. (%) 
ACEI/ARB 379/417 (90.9) 
Beta blockers 335/417 (80.3) 
Aldosterone antagonists 216/416 (51.9) 
Loop diuretics 312/408 (76.5) 
Thiazide diuretics 72/404 (17.8) 
Nitrates 50/415 (12.0) 
Digitalis 54/414 (13.0) 
Amiodarone 75/414 (18.1) 
Aspirin 193/417 (46.3) 
ADP antagonists 55/417 (13.2) 
Oral anticoagulation 200/417 (48) 
Lipid lowering therapy 247/416 (59.4) 
Calcium antagonists 24/414 (5.8) 
ACEI = angiotensin converting enzyme inhibitor, ADP antagonist = adenosine diphosphate re-
ceptor antagonist; ARB = angiotensin II receptor blocker.  
Data are presented as patient number per total number and percent total. 
 
  
 Table S3: Echocardiographic characteristics at the time of cardiac resynchronisation therapy 
device implantation. 
Left ventricular ejection fraction – % (n = 412) 26 (20–32) 
Left ventricular end-diastolic volume – ml/m2 (n = 344) 100.9 (82.0–128.8) 
Left ventricular endsystolic volume – ml/m2 (n = 344) 73.4 (57.9–100.8) 
Left ventricular end-diastolic diameter – mm (n = 374) 65 (60–72) 
Left ventricular endsystolic diameter – mm (n = 360) 55 (48–63) 
Left ventricular fractional shortening – % (n = 358) 16 (11–21) 
Right ventricular diastolic area – cm2 (n = 201) 19 (15–25) 
Right ventricular fractional area change – % (n = 211) 38 (37–48) 
Tricuspid Annulus Movement – mm (n = 250) 17 (13–20) 
Systolic RV over RA pressure – mm Hg (n = 309) 30 (23–40) 
Mitral insufficiency– no. / total no. (%)  
None  10/389 (2.6) 
Grade 1 101/389 (26) 
Grade 2 154/389 (39.6) 
Grade 3 101/389 (26) 
Grade 4 23/389 (5.9) 
Diastolic dysfunction – no. / total no. (%)  
None 35/198 (17.7) 
Grade 1 (abnormal relaxation) 82/198 (41.4) 
Grade 2 (pseudonormal relaxation pattern) 23/198 (11.6) 
Grade 3 (reversible restrictive relaxation pattern) 34/198 (17.2) 
Grade 4 (irreversible restrictive relaxation pattern) 24/198 (12.1) 
RA = right atrial; RV = right ventricle 
Categorical variables are presented as patient number per total number and percent total. 
Continuous variables are presented as median and interquartile range. 
 
Table S4: Electrocardiographic characteristics at the time of cardiac resynchronisation therapy 
device implantation. 
Rhythm  
Sinus rhythm – no. / total no. (%) 293/417 (70.3) 
Atrial fibrillation – no. / total no. (%) 46/417 (11) 
Right ventricle paced – no. / total no. (%) 78/417 (18.7) 
Atrioventricular conduction  
PQ – ms 189 (165–214) 
AVB I° – no. / total no. (%) 95/410 (23.2) 
AVB II° Mobitz 1 – no. / total no. (%) 3/410 (0.7) 
AVB II° Mobitz 2 – no. / total no. (%) 7/410 (1.7) 
AVB III° – no. / total no. (%) 25/410 (6.0) 
Intraventricular conduction  
QRS – ms 151 (130–170) 
QRS 120 ms – no. / total no. (%) 57/342 (16.7) 
QRS >120 ms to 150 ms – no. / total no. (%) 111/342 (32.5) 
QRS >150 ms – no. / total no. (%) 174/342 (50.9) 
No BBB – no. / total no. (%) 45/344 (13.1) 
Incomplete RBBB – no. / total no. (%) 3/344 (0.9) 
RBBB – no. / total no. (%) 19/344 (5.5) 
Incomplete LBBB – no. / total no. (%) 7/344 (2.0) 
LBBB – no. / total no. (%) 247/344 (71.8) 
Unspecific intraventricular block – no. / total no. (%) 21/344 (6.1) 
AVB = atrioventricular block; BBB = bundle-branch block; LBBB = left bundle-branch block; 
RBBB= right bundle-branch block 
Categorical variables are given as patient number per total number and percent, conduction 
times are presented in ms as median and interquartile ranges. Patients with right ventricular 
pacing at baseline were excluded from intraventricular conduction data. 
 
  
 Table S5A: Perioperative characteristics and devices. 
Time of surgery – min 100 (72–130) 
Time of fluoroscopy – min 15.5 (11.5–23.7) 
CRT-D – no. / total no. (%) 366/418 (87.6) 
De novo implantation – no. / total no. (%) 265/418 (63.4) 
PM upgrade – no. / total no. (%) 124/418 (29.7) 
ICD upgrade – no. / total no. (%) 29/418 (6.9) 
Successful LV lead placement in initial attempt (transvenous or epicardial) – no. / total no. (%) 366/418 (87.6) 
Successful LV lead placement in second attempt (transvenous or epicardial) – no. / total no. (%) 52/418 (12.4) 
Epicardial LV lead placement – no. / total no. (%) 48/418 (11.5) 
Device vendor  
Biotronik – no. / total no. (%) 153/418 (36.6) 
Boston Scientific – no. / total no. (%) 30/418 (7.2) 
Medtronic – no. / total no. (%) 139/418 (33.3) 
Sorin – no. / total no. (%) 4/419 (1.0) 
St. Jude Medical – no. / total no. (%) 92/418 (22.0) 
CRT-D = cardiac resynchronisation therapy-defibrillator; PM = pacemaker; ICD = implantable cardioverter defibrillator; LV = left ventricular 
Continuous variables are presented as median and interquartile rang. Categorical variables are presented as patient number per total number and percent total.  
 
Table S5B: Peri- and postoperative complications. 
 No. / total no. (%) 
Coronary sinus dissection 5/417 (1.2) 
Left ventricular lead dislocation 23/417 (5.5) 
Diaphragmatic capture 44/417 (10.6) 
Intermittent, no intervention 11/417 (2.6) 
Successful reprogramming 26/417 (6.2) 
Successful lead repositioning 5/417 (1.2) 
Termination of left ventricular pacing 2/417 (0.5) 
Infection 19/418 (4.5) 
Conservative management 9/418 (2.2) 
Device/lead explantation 10/418 (2.4) 
Coronary sinus perforation 2/418 (0.5) 
Pneumothorax 14/416 (3.4) 
Haematoma, conservative management 17/416 (4.1) 
Haematoma, operative management 9/416 (2.2) 
Data are presented as patient number per number and percent within the respective group. 
 
Table S6: Echocardiographic therapy response stratified by bundle branch block morphology. 
Rhythm at baseline No. / total no. (%) 
No LBBB LBBB 
LVEF improvement >5% 43/83 (51.8) 139/222 (62.6) 
LVEF improvement 10% 29/85 (34.1) 90/223 (40.4) 
EDVI reduction 10% 27/67 (40.3) 94/176 (53.4) 
EDVI reduction 20% 15/67 (22.4) 60/176 (34.1) 
EDVI = end-diastolic volume index; LVEF = left ventricular ejection fraction 
Data are presented as patient number per number and percent within the respective group. 
 
